Merck & Co. MRK Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73.9%-0.9pp | 74.8%-2.4pp | 77.2%+0.6pp | 76.6%+0.2pp | 76.4%+0.1pp | |
| Net margin | 13.6%-14.5pp | 28.1%-1.6pp | 29.6%+3.8pp | 25.8%-1.5pp | 27.3%+0.6pp | |
| Returns | ||||||
| Return on equity | 19%-17.9pp | 36.9%-2.6pp | 39.5%+4.1pp | 35.4%-3.9pp | 39.3%-1.5pp | |
| Return on invested capital | 10.8%-11.4pp | 22.2%-3.6pp | 25.8%+4.1pp | 21.8%-1.9pp | 23.6%-0.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.6×0.0× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.3×-0.2× | 1.5×-0.1× | 1.7×+0.2× | 1.4×0.0× | 1.4×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 1.1×+0.1× | 1×+0.2× | 0.8×+0.1× | 0.8×0.0× | 0.7×-0.1× | |
| Net debt / EBITDA | 3×+1.4× | 1.6×+0.6× | 1×-0.3× | 1.4×+0.1× | 1.2×0.0× | |
| Valuation | ||||||
| Market capitalization | $297.4B+13.8% | $261.26B+24.6% | $209.64B+3.9% | $201.69B-11.0% | $226.74B-9.9% | |
| Price / earnings | 33.3×+19.0× | 14.3×+3.3× | 11×-1.3× | 12.3×-0.7× | 13×-1.7× | |
| Price / sales | 4.5×+0.5× | 4×+0.8× | 3.3×+0.1× | 3.2×-0.4× | 3.5×-0.4× | |
| Price / book | 6.5×+1.5× | 5×+0.9× | 4×-0.1× | 4.1×-0.6× | 4.7×-0.7× | |
| EV / EBITDA | 23.1×+10.7× | 12.4×+2.6× | 9.8×-1.0× | 10.8×-0.6× | 11.4×-1.2× | |
| Dividend yield | 2.8%-0.4pp | 3.1%-0.7pp | 3.9%-0.1pp | 4%+0.5pp | 3.5%+0.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Merck & Co.'s ratios come from?
- Every ratio is computed from Merck & Co.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
